Created at the initiative of several cancer centres in and outside of Europe, the Oncodistinct Network is a multidisciplinary group of investigators with an expertise in early drug development and clinical research.
Together, we aim to address the current challenges in oncology and improve patients’ outcomes by developing innovative clinical studies and accelerating the development of anti-cancer drugs in solid tumors, particularly in settings with unmet medical needs.
The network brings together more than 20 cancer centres and university hospitals. Oncodistinct is built on tight collaborations between oncologists, organ specialists, radiotherapists and scientists of each Oncodistinct site as well as pharmaceutical companies.
Since 2024, OncoDistinct operates as an ASBL (non profit organization).
On top of regular contacts, Oncodistinct members meet twice a year to pursue scientific collaborations, set-up clinical trials and think together about new projects for the network.
Gatherings with pharmaceutical industries are a good opportunity to develop the network and to start new collaborations. Meet the Industry meetings intend to select a few pharma representatives to present projects that could be of interest for the network.
A network composed of comprehensive cancer centers and university hospitals with expertise in oncology. The centers closely work together to contribute to a common project.
